SCHEMBL6979588

SCHEMBL6979588

COc1ccccc1-c1noc(C(C)C)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.61
SMN1; SMN2 Q16637 10/20 0.61
TP53 P04637 8/20 0.61
NPC1 O15118 8/20 0.61
ALDH1A1 P00352 5/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
POLB P06746 1/20 0.57
S1PR1 P21453 3/20 0.56
KDM4E B2RXH2 6/20 0.56
HSD17B10 Q99714 6/20 0.56
TSHR P16473 4/20 0.56
HPGD P15428 3/20 0.56
NPSR1 Q6W5P4 2/20 0.56
GAA P10253 2/20 0.54
HTT P42858 2/20 0.53
PKM P14618 1/20 0.52
MAPT P10636 2/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24923579 0.85 SMN1; SMN2 (0.56) RAB9ASMN1; SMN2TP53NPC1ALDH1A1
SCHEMBL6979594 0.85 RAB9A (0.51) RAB9ASMN1; SMN2TP53NPC1ALDH1A1
SCHEMBL20853255 0.80 SMN1; SMN2 (0.57) RAB9ASMN1; SMN2NPC1ALDH1A1L3MBTL1
SCHEMBL15479735 0.79 HTT (0.57) RAB9ASMN1; SMN2TP53NPC1ALDH1A1
SCHEMBL1250902 0.79 SMN1; SMN2 (0.67) RAB9ASMN1; SMN2TP53NPC1ALDH1A1
SCHEMBL6976168 0.78 HTT (0.55) RAB9ASMN1; SMN2TP53NPC1ALDH1A1
SCHEMBL6979612 0.78 KMT2A (0.56) RAB9ASMN1; SMN2TP53NPC1ALDH1A1
SCHEMBL6979805 0.77 DPP4 (0.57) RAB9AALDH1A1S1PR1KDM4EHSD17B10
SCHEMBL18584968 0.77 RAB9A (0.68) RAB9ASMN1; SMN2TP53NPC1ALDH1A1
SCHEMBL17514013 0.76 SMN1; SMN2 (0.52) RAB9ASMN1; SMN2TP53NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787780-B2 Quaternary indazole glucocorticoid receptor antagonists CORCEPT THERAPEUTICS INCORPORATED (US) 2023-10-17 US disclosed
US-11787780-B2 Quaternary indazole glucocorticoid receptor antagonists CORCEPT THERAPEUTICS INCORPORATED (US) 2023-10-17 US disclosed
US-20230032612-A1 QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS CORCEPT THERAPEUTICS INCORPORATED 2023-02-02 US disclosed
US-20190262371-A1 METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-08-29 US disclosed
US-8183276-B2 Therapeutic agents MERCK SHARP & DOHME CORP. 2012-05-22 US disclosed
US-20100324029-A1 THERAPEUTIC AGENTS MERCK SHARP & DOHME CORP. 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787780-B2 Quaternary indazole glucocorticoid receptor antagonists NR3C1, NR3C2, MC2R RAB9A 3949/4885SMN1; SMN2 4861/4885TP53 3110/4885
US-20230032612-A1 QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS NR3C1, NR3C2, MC2R RAB9A 3949/4885SMN1; SMN2 4861/4885TP53 3110/4885
US-20190262371-A1 METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS POLRMT, EIF2AK2, NSUN3 RAB9A 2724/4885SMN1; SMN2 959/4885TP53 583/4885
US-20100324029-A1 THERAPEUTIC AGENTS PSEN2, PSEN1, BACE2 RAB9A 2575/4885SMN1; SMN2 233/4885TP53 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.